Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) Short Interest Update

Virpax Pharmaceuticals, Inc. (NASDAQ:VRPX) was the target of a large decrease in short interest during the month of October. As of October 31st, there was short interest totalling 350,900 shares, a decrease of 37.9% from the October 15th total of 565,500 shares. Based on an average daily trading volume, of 281,500 shares, the days-to-cover ratio is presently 1.2 days. Approximately 7.6% of the company’s stock are short sold.

Virpax Pharmaceuticals Stock Performance

Shares of NASDAQ:VRPX traded up $0.02 on Thursday, hitting $0.64. The company’s stock had a trading volume of 106,472 shares, compared to its average volume of 1,806,374. The company has a 50-day simple moving average of $0.68 and a 200 day simple moving average of $0.96. Virpax Pharmaceuticals has a 1 year low of $0.36 and a 1 year high of $8.00.

Virpax Pharmaceuticals (NASDAQ:VRPX) last announced its quarterly earnings data on Monday, August 12th. The company reported ($1.75) earnings per share for the quarter.

Analyst Upgrades and Downgrades

Separately, Maxim Group reaffirmed a “hold” rating on shares of Virpax Pharmaceuticals in a research report on Wednesday, October 9th.

About Virpax Pharmaceuticals

Virpax Pharmaceuticals, Inc, a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical spray film delivery technology for osteoarthritis pain; Probudur, an injectable local anesthetic liposomal gel technology for postoperative pain management; and Envelta, a nanotechnology-based intranasal spray drug product candidate that enables the delivery of a metabolically labile peptide drug into the brain.